Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys
- PMID: 10644345
- PMCID: PMC111650
- DOI: 10.1128/jvi.74.4.1742-1751.2000
Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys
Abstract
ChimeriVax-JE is a live, attenuated recombinant virus prepared by replacing the genes encoding two structural proteins (prM and E) of yellow fever 17D virus with the corresponding genes of an attenuated strain of Japanese encephalitis virus (JE), SA14-14-2 (T. J. Chambers et al., J. Virol. 73:3095-3101, 1999). Since the prM and E proteins contain antigens conferring protective humoral and cellular immunity, the immune response to vaccination is directed principally at JE. The prM-E genome sequence of the ChimeriVax-JE in diploid fetal rhesus lung cells (FRhL, a substrate acceptable for human vaccines) was identical to that of JE SA14-14-2 vaccine and differed from sequences of virulent wild-type strains (SA14 and Nakayama) at six amino acid residues in the envelope gene (E107, E138, E176, E279, E315, and E439). ChimeriVax-JE was fully attenuated for weaned mice inoculated by the intracerebral (i.c.) route, whereas commercial yellow fever 17D vaccine (YF-Vax) caused lethal encephalitis with a 50% lethal dose of 1.67 log(10) PFU. Groups of four rhesus monkeys were inoculated by the subcutaneous route with 2.0, 3.0, 4.0, and 5. 0 log(10) PFU of ChimeriVax-JE. All 16 monkeys developed low viremias (mean peak viremia, 1.7 to 2.1 log(10) PFU/ml; mean duration, 1.8 to 2.3 days). Neutralizing antibodies appeared between days 6 and 10; by day 30, neutralizing antibody responses were similar across dose groups. Neutralizing antibody titers to the homologous (vaccine) strain were higher than to the heterologous wild-type JE strains. All immunized monkeys and sham-immunized controls were challenged i.c. on day 54 with 5.2 log(10) PFU of wild-type JE. None of the immunized monkeys developed viremia or illness and had mild residual brain lesions, whereas controls developed viremia, clinical encephalitis, and severe histopathologic lesions. Immunized monkeys developed significant (>/=4-fold) increases in serum and cerebrospinal fluid neutralizing antibodies after i.c. challenge. In a standardized test for neurovirulence, ChimeriVax-JE and YF-Vax were compared in groups of 10 monkeys inoculated i.c. and analyzed histopathologically on day 30. Lesion scores in brains and spinal cord were significantly higher for monkeys inoculated with YF-Vax. ChimeriVax-JE meets preclinical safety and efficacy requirements for a human vaccine; it appears safer than yellow fever 17D vaccine but has a similar profile of immunogenicity and protective efficacy.
Figures
Similar articles
-
Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.Viruses. 2013 Dec 9;5(12):3048-70. doi: 10.3390/v5123048. Viruses. 2013. PMID: 24351795 Free PMC article. Review.
-
Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities.Vaccine. 2010 May 7;28(21):3635-41. doi: 10.1016/j.vaccine.2010.02.105. Epub 2010 Mar 11. Vaccine. 2010. PMID: 20226891 Review.
-
Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines.J Virol. 2002 Feb;76(4):1932-43. doi: 10.1128/jvi.76.4.1932-1943.2002. J Virol. 2002. PMID: 11799188 Free PMC article.
-
Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.Virology. 1999 May 10;257(2):363-72. doi: 10.1006/viro.1999.9695. Virology. 1999. PMID: 10329547
-
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.Vaccine. 1999 Apr 9;17(15-16):1869-82. doi: 10.1016/s0264-410x(98)00487-3. Vaccine. 1999. PMID: 10217584
Cited by
-
Generation and characterization of chimeric Tembusu viruses containing pre-membrane and envelope genes of Japanese encephalitis virus.Front Microbiol. 2023 Jun 22;14:1140141. doi: 10.3389/fmicb.2023.1140141. eCollection 2023. Front Microbiol. 2023. PMID: 37426013 Free PMC article.
-
Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development.Viruses. 2023 Mar 23;15(4):813. doi: 10.3390/v15040813. Viruses. 2023. PMID: 37112794 Free PMC article. Review.
-
Chimeric Vaccines Based on Novel Insect-Specific Flaviviruses.Vaccines (Basel). 2021 Oct 22;9(11):1230. doi: 10.3390/vaccines9111230. Vaccines (Basel). 2021. PMID: 34835160 Free PMC article. Review.
-
Live Viral Vaccine Neurovirulence Screening: Current and Future Models.Vaccines (Basel). 2021 Jun 30;9(7):710. doi: 10.3390/vaccines9070710. Vaccines (Basel). 2021. PMID: 34209433 Free PMC article. Review.
-
A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice.NPJ Vaccines. 2020 Aug 5;5(1):73. doi: 10.1038/s41541-020-00220-4. eCollection 2020. NPJ Vaccines. 2020. PMID: 32802412 Free PMC article.
References
-
- Aihara S, Rao C M, Yu Y X. Identification of mutations that occurred on the genome of Japanese encephalitis virus during the attenuation process. Virus Genes. 1991;5:95–109. - PubMed
-
- Chambers T J, Tsai T F, Pervikov Y, Monath T P. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine. 1997;15:1494–1502. - PubMed
-
- Chen W R, Tesh R B, Rico-Hesse R. Genetic variation of Japanese encephalitis virus in nature. J Gen Virol. 1990;71:2915–2920. - PubMed
-
- Chen W R, Rico-Hesse R, Tesh R B. A new genotype of Japanese encephalitis from Indonesia. Am J Trop Med Hyg. 1992;47:61–69. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical